Active clinical trials for "Vision Disorders"

Background: One of the most difficult refractory glaucomas in treatment is the neovascular type and its association with dense cataract add to this difficulty. This study aimed to provide results of triple surgical treatment of such conditions. Methods: A total of 12 eyes of 12 patients with dense cataractus NVG patients were included in this study. The patients mean age was 57.25 ± 5.9 years. The mean pre-operative intraocular pressure (IOP) was 47.25 ± 4.04 mmHg with maximum antiglaucoma therapy. The mean best corrected distant visual acuities (BCDVA) in log MAR was 2.13 ± 0.38. All the patients received intra-vitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including pan-retinal photocoagulation (PRP), and assisted trabeculectomy with Mitomycin c (MMC). Mean IOP and BCDVA changes were the main outcome results of this study.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).

Approximately 24,500 children and young people (CYP) in England have a visual impairment (VI). VI refers to a loss of vision that cannot be corrected with glasses or contact lenses. Low vision aids (e.g. magnifying glasses) can help CYP with a VI see more clearly. However, current low vision aids are not suitable for many of the activities CYP regularly engage in, such as watching TV or school lessons. SightPlus is an advanced head-mounted digital low vision aid for CYP and adults. SightPlus helps people with a VI use their remaining vision to see more clearly up close and at a distance. SightPlus was recently tested at Moorfields Eye Hospital in London with 60 adults with a VI. The results showed that adults could see more clearly while using SightPlus. The study proposed here aims to find out whether SightPlus can improve the vision and quality of life of CYP aged 8-16 years with a VI. For this study, 25 CYP will come to Sheffield Children's Hospital (SCH) for an 80-minute session with parents/guardians where they will have their vision tested, complete questionnaires measuring their vision-related quality of life and functional vision (i.e. what someone can see), and learn how to use SightPlus. CYP will then be asked to use SightPlus for four weeks. Parents/guardians will record the activities CYP use SightPlus for in a home diary. After four weeks, CYP and their parents/guardians will come back to SCH for a 90-minute session where they will have their vision tested with and without SightPlus, complete another vision-related quality of life and functional vision questionnaire, hand in their home diary, and complete a feedback form about their experiences of using SightPlus. This study will help us find out whether SightPlus can improve the vision and quality of life of CYP with a VI.

The aim of our study is to examine the effects of eight sessions of online social skills training given to visually impaired adolescents on social skills, self-efficacy, social phobia and social integration. Forty visually impaired adolescents between the ages of 13 and 19 participated in the study. Participants were divided into control and training groups. 20 adolescents were included in the education program. All participants included in the study were evaluated using the Sociodemographic Information Form, Social Skills Assessment Scale for Children, General Self-Efficacy Scale, Child and Adolescent Social Phobia Scale, and Social Integration Questionnaire.

This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular Edema (DME).

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches. It is a Prospective randomized double masked two arm performed on a minimum of 200 to a maximum of 300 subjects identified as symptomatic (HIT-6 questionnaire score equal to or greater than 56) done across 3-15 clinical sites. There are two subgroups: a minimum of 100 in each subgroup (subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects (41-60 years).

This study is a multi-site, 5-visit dispensing, bilateral double-arm parallel group design, double-masked clinical trial using an investigational contact lens and a marketed contact lens. The objective is to evaluate comfort of the contact lenses when worn on a daily wear modality.

The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease after the first administration of ranibizumab.